Novacea, Inc. Provides Update on Ascent-2 Protocol Amendment

SOUTH SAN FRANCISCO, CA--(Marketwire - October 30, 2007) - Novacea, Inc. (NASDAQ: NOVC) announced today that representatives from the company and Schering-Plough (NYSE: SGP) are finalizing the ASCENT-2 protocol with the U.S. Food and Drug Administration (FDA). ASCENT-2 is a Phase 3 clinical trial of Asentar™ (DN-101) for the treatment of patients with androgen independent prostate cancer or AIPC. The study is comparing the benefits of weekly Asentar plus Taxotere® (docetaxel) to the current standard of care in the treatment of AIPC.

Back to news